Document Detail

A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia.
MedLine Citation:
PMID:  21788997     Owner:  NLM     Status:  In-Data-Review    
Objective To identify whether sarsasapogenin, a sapogenin from the Chinese medicinal herb Anemarrhena Asphodeloides Bunge, would augment the efficacy of risperidone and significantly improve cognitive functions in patients with negative symptoms dominated schizophrenia. Methods The trial was a double-blind, placebo-controlled, parallel-group design. The eligible patients were randomized into 2 treatment groups: sarsasapogenin group (sarsasapogenin plus risperidone for 8 weeks, n = 41) and placebo group (risperidone only for 8 weeks, n = 39). At the baseline, as well as at weeks 2, 4 and 8 of treatment, the therapeutic response was measured by using scales including Positive and Negative Symptoms Scale (PANSS), Wechsler Memory Scale (WMS), modified Chinese Wechsler Adult Intelligence Scale (mWAIS), Clinical Global Impression (CGI) and Brief Psychiatry Rating Scale (BPRS). The study period for each subject was 8 weeks and duration of overall trial was 2 years. Results Patients treated with sarsasapogenin plus risperidone demonstrated no statistically significant differences in changes in PANSS, WMS or mWAIS score at the end-point of the trial compared with patients treated with placebo plus risperidone. The incidence of treatment-emergent adverse events in patients treated with sarsasapogenin was not different from that observed in placebo group. Conclusion Sarsasapogenin did not augment the efficacy of risperidone in treating negative symptoms dominated schizophrenia. Sarsasapogenin at a dosage of 200 mg per day added to a flexible dosage of risperidone at 2-4 mg per day is safe and well tolerated by patients with negative symptoms dominated schizophrenia.
Shi-Fu Xiao; Hai-Bo Xue; Xia Li; Chao Chen; Guan-Jun Li; Cheng-Mei Yuan; Ming-Yuan Zhang
Related Documents :
22075737 - Serum brain-derived neurotrophic factor (bdnf): the severity and symptomatic dimensions...
25266907 - Factors affecting acceptability of an email-based intervention to increase fruit and ve...
22749527 - Fatigue mediates the relationship between physical fitness and quality of life in cance...
19546097 - Oral treatment with a brachystemma calycinum d don plant extract reduces disease sympto...
8834417 - Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimepraz...
8917157 - Cynicism, hostility, and suicidal ideation in depressed outpatients.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Neuroscience bulletin     Volume:  27     ISSN:  1995-8218     ISO Abbreviation:  Neurosci Bull     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-07-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101256850     Medline TA:  Neurosci Bull     Country:  China    
Other Details:
Languages:  eng     Pagination:  258-68     Citation Subset:  IM    
Geriatric Psychiatry Department, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai 200030, China; E-mail:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Diagnostic value of amplitude-integrated electroencephalogram in neonatal seizures.
Next Document:  Angiotensin II-derived reactive oxygen species underpinning the processing of the cardiovascular ref...